Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience

#101

Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.

Aim(s): To assess the long-term complications following treatment with PRRT. The main categories were hematologic, renal and endocrine side effects. The role of precipitating factors, type and dose of radiotherapy were also assessed.

Materials and methods: We retrospectively analyzed our data of 90 consecutive patients with different GEPNETs who received PRRT. CBC and renal function tests were performed prior to treatment and every two weeks following each treatment cycle for a minimum of eight weeks. Patients’ files were reviewed for the identification of possible risk factors for developing both renal and hematologic complications. For the purpose of this report, only patients with either hematological or renal complications that persisted for over eight weeks from the last PRRT treatment were included. Three women who developed premature ovarian failure were assessed for pituitary gonadal axis function. The CTCAE version 3 NIH/NCI adverse event grading system was used to quantify severity of adverse events.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Fraenkel M, Barak D, Mueller-Brand J, Krausz Y, Glaser B,

Keywords: PRRT, chronic complications, GEPNET,